Bank of America discloses 6.7% stake in Fulcrum
Bank of America Corporation, through certain wholly owned subsidiaries, reports beneficial ownership of common stock of Fulcrum Therapeutics, Inc..
Rhea-AI Filing Summary
Bank of America Corporation, through certain wholly owned subsidiaries, reports beneficial ownership of common stock of Fulcrum Therapeutics, Inc..
The group holds 4,468,123 shares of Fulcrum Therapeutics common stock, representing 6.7% of the outstanding class, based on 66,633,321 shares outstanding as reported by Fulcrum Therapeutics in its Form 10-Q for share totals as of April 20, 2026. All reported shares are held with shared voting and shared dispositive power; Bank of America and its reporting subsidiaries have no sole voting or dispositive power over these shares. The filing is made jointly on behalf of Bank of America Corporation and its wholly owned subsidiaries BofA Securities, Inc., Bank of America N.A., and Merrill Lynch International.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
beneficial ownership financial
parent holding company financial
broker dealer financial
non-U.S. institution financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Fulcrum Therapeutics (FULC) does Bank of America report owning?
Which Bank of America entities hold the reported Fulcrum Therapeutics (FULC) position?
AI-generated analysis. How Rhea-AI works. Not financial advice.